Ben-Arye Eran, Schiff Elad, Mutafoglu Kamer, Omran Suha, Hajjar Ramzi, Charalambous Haris, Dweikat Tahani, Ghrayeb Ibtisam, Sela Gil Bar, Turker Ibrahim, Hassan Azza, Hassan Esmat, Popper-Giveon Ariela, Saad Bashar, Nimri Omar, Kebudi Rejin, Dagash Jamal, Silbermann Michael
Integrative Oncology Program, The Oncology Service and Lin Medical Center, Clalit Health Services, 35 Rothschild St., Haifa, Western Galilee District, Israel,
Support Care Cancer. 2015 Sep;23(9):2605-12. doi: 10.1007/s00520-015-2619-7. Epub 2015 Jan 24.
In this multinational Middle-Eastern study, we assessed health-care providers' (HCPs) perspectives on their patients' use of complementary and traditional medicine (CTM) and identified the leading barriers to CTM integration in supportive cancer care.
A 17-item questionnaire was developed and administered to HCPs attending palliative medicine workshops conducted across the Middle East by the Middle East Cancer Consortium.
339 HCPs from 16 countries across the Middle East completed the questionnaire (80.3 % response rate). Respondents perceived their patients' reasons for CTM use primarily in the context of cancer cure (63 %) and quality of life (QOL) improvement (57 %). Expectation regarding CTM's role in cancer cure/survival was more pronounced in Turkey, Jordan, the Palestinian Authority, and the Persian Gulf area. In contrast, the expectation that CTM would improve QOL was more emphasized in Israel. A mid-position between the cure/survival and QOL poles was observed in Cyprus, Lebanon, and the North African countries. Leading barriers to CTM integration in supportive cancer care included oncologists' skepticism and a gap between patients' expectations and HCP's objectives. Respondents' leading recommendation to HCPs was to communicate integrative care emphasizing well-being and improved functioning in accordance with their patients' health beliefs.
CTM integration in supportive cancer care can be facilitated by implementing a platform for Middle Eastern clinical collaborations. HCPs' expectations and experiences with CTM have been positive in the oncology setting. These data need to be corroborated with information of patients' expectations on the provision of CTM over all phases of the oncology treatment.
在这项中东地区的跨国研究中，我们评估了医疗保健提供者（HCPs）对其患者使用补充和传统医学（CTM）的看法，并确定了在支持性癌症护理中整合CTM的主要障碍。
编制了一份包含17个条目的问卷，并向参加中东癌症联盟在中东各地举办的姑息医学研讨会的HCPs发放。
来自中东16个国家的339名HCPs完成了问卷（回复率为80.3%）。受访者认为其患者使用CTM的主要原因在于癌症治愈（63%）和生活质量（QOL）改善（57%）。在土耳其、约旦、巴勒斯坦权力机构和波斯湾地区，对CTM在癌症治愈/生存方面作用的期望更为明显。相比之下，以色列更强调CTM能改善生活质量的期望。在塞浦路斯、黎巴嫩和北非国家，观察到在治愈/生存和生活质量两极之间处于中间位置。在支持性癌症护理中整合CTM的主要障碍包括肿瘤学家的怀疑态度以及患者期望与HCP目标之间的差距。受访者给HCPs的主要建议是根据患者的健康信念，传达强调幸福感和功能改善的综合护理。
通过建立中东临床合作平台，可以促进在支持性癌症护理中整合CTM。在肿瘤学环境中，HCPs对CTM的期望和体验是积极的。这些数据需要与患者在肿瘤治疗各阶段对提供CTM的期望信息相互印证。
